Released Feb 28, 2022, after the close
10-K filed Feb 28, 2022, 59 days after period end · 0000950170-22-002312
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$10.65M$10.65M derived+28.7% vs Q4 2020+25.1% vs Q3 2021
Net Income-$38.13M-$38.13M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$35,036,000N/M
Operating Cash Flowderived-$21,580,000N/M
Margins · derived
Operating margin-328.9%−28.7 pt vs Q4 2020
Net margin-357.8%+361.5 pt vs Q4 2020
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $10.65M | $8.28M | $11.31M | $19.09M |
| Net Income | -$38.13M | -$59.54M | -$14.79M | -$1.49M |
| EPS Diluted | — | -$1.48 | -$0.65 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR